AngioDynamics’ “Partnerships in Clinical Trial Engagements” Initiative Seeks to Increase Patient Participation in Underserved Communities

March 8, 2023—AngioDynamics, Inc. announced the commencement of its Partnerships in Clinical Trial Engagements (PCTE) initiative, which aims to increase patient involvement in clinical trials in underrepresented communities by offering grants to health care providers.

According to AngioDynamics, these PCTE grants will develop relationships or programs that aim to advance health care by producing more inclusive clinical trial data. The company advised that it is committed to educating key constituencies about the current clinical study landscape and addressing disparities in health care through this PCTE initiative.

PCTE emphasizes building mutually beneficial relationships between health care providers and underrepresented patient populations. Through this collaboration, solutions will be developed to advance health equity, stated the company.

“We believe every patient deserves access to quality care, and clinical trials should reflect the diversity of society,” commented Juan Carlos Serna, Senior VP, Scientific & Clinical Affairs, at AngioDynamics. “Our PCTE initiative is our commitment to ensuring everyone has an equal chance to participate in important studies.”

More information about the Partnerships in Clinical Trial Engagements is available on the company’s website at www.angiodynamics.com/pcte.

AngioDynamics advised it is currently enrolling patients in three United States investigational device exemption clinical studies:

• PRESERVE.  FDA approval to conduct the PRESERVE study for the treatment of prostate cancer with the company’s NanoKnife system was announced in August 2021.
• APEX-AV.  The commencement of the APEX-AV study of the treatment of pulmonary embolism with the company’s AlphaVac F18⁸⁵ system was announced in October 2022.
• DIRECT, a study composed of the DIRECT pivotal randomized control trial and the DIRECT real-world registry. FDA approval of the DIRECT study to evaluate the treatment of pancreatic cancer with the NanoKnife system, was announced in April 2019.